Abstract: Nucleic acid molecules encoding polypeptides having polyketide synthase activity have been identified and characterized. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.

Abstract: Methods and uses of activators of the APC complex for treating cancer in a subject, inhibiting the growth of a cancer cell, increasing sensitivity to a cancer treatment in a cancer cell or a subject and/or reducing resistance to a cancer treatment in a cancer cell or a subject.

Abstract: This application relates to compositions comprising one or more CpG oligodeoxynucleotides complexed to nanoparticles comprising a gemini surfactant and optionally a muco-adhesive polymer, which can be used for intrapulmonary delivery to induce immunity in feed animals, and the methods of making and uses thereof.

Abstract: The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of ?-glucocerebrosidase activity.

Abstract: Novel activators of the APC complex and methods and uses of these activators are provided. In particular, the activators are used for increasing resistance to stress and/or increasing lifespan in a plant or mammalian cell, in a plant or mammalian embryo or in a plant or subject. The activators are also used for treating cancer in a subject.

Abstract: This disclosure provides a preserving composition comprising a cholesterol: carrier complex, optionally a cholesterol:cyclodextrin complex (CC complex) and/or a cell permeable antioxidant peptide and a biological buffer and optionally a cryprotectant, wherein the preserving composition is optionally substantially free of animal phospholipid, animal protein and/or animal lipoprotein. The disclosure also provides methods for the use of the preserving composition in cryopreservation of semen or sperm cells. Also provided is a kit comprising the preserving composition having a CC complex, a biological buffer, a cryoprotectant, a carbohydrate, a pH stabilizer, an antibiotic or antibiotic cocktail and/or a cell permeable anti-oxidant peptide.

Abstract: Bifunctional molecules having first and second alpha-synuclein binding agents coupled by a linker are disclosed. The bifunctional molecules have potential utility in the diagnosis, treatment and/or prophylaxis of disorders in which alpha-synuclein is implicated, including Parkinson's disease. Methods of making and using the bifunctional molecules are disclosed.

Abstract: Novel airway devices and methods address complications of ventilating a patient with a mask; placing an endotracheal tube in an awake patient; and need for a bite block during flexible bronchoscopy and gastroscopy. The airway device features notches for engaging maxillary and mandibular teeth in a manner protracting the patient's mandible relative to the maxilla to open up the airway. This way, an open airway is easily maintained simply by holding the jaw closed against the device with the same hand used to operate a bag ventilator. A longitudinal channel in the device features a downwardly curved end wall for improved guidance of the endoscope into position. The channel is open sided at the top or bottom to allow rolling of the airway device off the endoscope into an offset position serving as a protective bite block and allowing feeding of the endotracheal tube along the endoscope.

Abstract: Described are methods and uses employing metabolomic data to diagnose an asthma disease state or a Chronic Obstructive Pulmonary Disease (COPD) state. Further described are methods of uses of employing metabolomic data to distinguish between asthma and COPD. In particular, urinary metabolomic profiles are employed to enable differential diagnosis of asthma and COPD.

Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind HER3. The disclosure is further directed to immunoconjugates comprising the antibodies and binding fragments thereof that specifically bind HER3. The disclosure is also directed to uses of the antibodies, binding fragments thereof and immunoconjugates for detecting HER3-expressing cells and for treating HER3-expressing cancer.

Abstract: The present application relates to combination treatments for bacterial infections. For example, the application relates to the use of tulathromycin and gallic acid for the treatment of a Mannheimia haemolytica and/or Pasteurella multocida bacterial infection or a disease, disorder or condition arising from a Mannheimia haemolytica and/or Pasteurella multocida bacterial infection.

Abstract: Nucleic acid molecules encoding polypeptides having polyketide synthase activity have been identified and characterized. Expression or over-expression of the nucleic acids alters levels of cannabinoid compounds in organisms. The polypeptides may be used in vivo or in vitro to produce cannabinoid compounds.

Abstract: The present disclosure relates to a method for detecting a brain injury in a subject by comparing the amount of ADAM10 protein in a blood sample from the subject to a reference standard or to the amount of ADAM10 in a blood sample from a control. An increase in the amount of ADAM10 in the subject blood sample relative to the reference standard or control is indicative of the subject having sustained a brain injury, in particular a traumatic brain injury (TBI). The present disclosure also provides novel antibody and antibody fragments that bind to ADAM10 at different positions.

Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.

Abstract: The present disclosure provides compositions comprising novel endophytes capable of promoting germination endophytes that have a symbiotic relationship with plants. The present disclosure further provides methods of improving seed vitality, biotic and abiotic stress resistance, plant health and yield under both stressed and unstressed environmental conditions, comprising inoculating a seed with the novel endophyte strains and cultivating a plant therefrom.

Abstract: The present disclosure provides novel endophyte strains or cultures thereof that have a symbiotic relationship with plants. The present disclosure further provides methods of improving seed vitality, biotic and abiotic stress resistance, plant health and yield under both stressed and unstressed environmental conditions, comprising inoculating a seed with the novel endophyte strains and cultivating a plant therefrom.

Abstract: Systems and methods of separating components of a multi-component gas mixture are described herein. The systems include one or more packed bed columns packed with a biosorbent material. Upon passing the multi-component gas mixture through the packed bed column, substantially all of a polar component of the multi-component gas mixture is adsorbed by the biosorbent material and a non-polar component of the multi-component gas mixture is not substantially adsorbed by the biosorbent material.

Abstract: The present application relates to combination treatments for bacterial infections. For example, the application relates to the use of tulathromycin and gallic acid for the treatment of a Mannheimia haemolytica and/or Pasteurella multocida bacterial infection or a disease, disorder or condition arising from a Mannheimia haemolytica and/or Pasteurella multocida bacterial infection.

Abstract: The present application relates to conduritol aziridines of Formula (I), and uses thereof, for example, of 18F-labelled derivatives thereof in positron-emission tomography (PET) imaging of ?-glucocerebrosidase activity.

Abstract: The disclosure provides methods of detecting and monitoring brain injury in a test subject comprising analyzing a blood sample from the test subject for increased levels of PrPC. The disclosure also provides kits for measuring the amount of PrPC in a blood sample.